X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3936) 3936
Publication (253) 253
Book Review (16) 16
Magazine Article (10) 10
Book Chapter (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3138) 3138
atorvastatin calcium (2962) 2962
male (2765) 2765
female (2175) 2175
heptanoic acids - therapeutic use (2089) 2089
pyrroles - therapeutic use (2024) 2024
middle aged (1887) 1887
atorvastatin (1789) 1789
index medicus (1621) 1621
heptanoic acids - pharmacology (1321) 1321
aged (1312) 1312
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1169) 1169
statins (1162) 1162
pyrroles - pharmacology (1160) 1160
heptanoic acids - administration & dosage (1066) 1066
pyrroles - administration & dosage (1047) 1047
adult (1020) 1020
animals (962) 962
cholesterol, ldl - blood (882) 882
anticholesteremic agents - therapeutic use (880) 880
cholesterol (875) 875
cardiac & cardiovascular systems (844) 844
treatment outcome (830) 830
simvastatin (683) 683
pharmacology & pharmacy (678) 678
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (644) 644
hypercholesterolemia - drug therapy (590) 590
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (583) 583
atherosclerosis (546) 546
cholesterol - blood (543) 543
pravastatin (524) 524
double-blind method (491) 491
peripheral vascular disease (485) 485
rats (482) 482
dose-response relationship, drug (480) 480
heptanoic acids - adverse effects (467) 467
risk factors (461) 461
pyrroles - adverse effects (456) 456
triglycerides - blood (447) 447
hypercholesterolemia (430) 430
lipids - blood (394) 394
drug therapy, combination (390) 390
antilipemic agents (389) 389
anticholesteremic agents - administration & dosage (388) 388
cholesterol, hdl - blood (384) 384
prospective studies (372) 372
time factors (369) 369
inflammation (362) 362
lipids (360) 360
simvastatin - therapeutic use (359) 359
prevention (340) 340
anticholesteremic agents - pharmacology (338) 338
hypercholesterolemia - blood (322) 322
risk (317) 317
disease (307) 307
c-reactive protein (301) 301
drug therapy (298) 298
medicine, general & internal (293) 293
coronary-heart-disease (292) 292
cardiovascular (288) 288
statin (287) 287
therapy (286) 286
mice (282) 282
hyperlipidemias - drug therapy (281) 281
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (280) 280
follow-up studies (277) 277
analysis (274) 274
biomarkers - blood (259) 259
rosuvastatin calcium (248) 248
expression (242) 242
cardiovascular disease (235) 235
care and treatment (233) 233
pravastatin - therapeutic use (232) 232
myocardial-infarction (228) 228
coronary heart disease (227) 227
cardiovascular-disease (223) 223
research (221) 221
low density lipoproteins (217) 217
efficacy (216) 216
coa reductase inhibitors (212) 212
aged, 80 and over (210) 210
abridged index medicus (208) 208
oxidative stress (207) 207
safety (207) 207
anticholesteremic agents - adverse effects (204) 204
endocrinology & metabolism (203) 203
statin therapy (203) 203
disease models, animal (202) 202
cardiovascular agents (198) 198
cardiovascular diseases - prevention & control (189) 189
endothelium, vascular - drug effects (188) 188
dyslipidemias - drug therapy (186) 186
cholesterol, ldl - drug effects (185) 185
hypertension (179) 179
heptanoic acids - pharmacokinetics (178) 178
rosuvastatin (178) 178
c-reactive protein - metabolism (177) 177
nitric-oxide synthase (172) 172
drug administration schedule (171) 171
events (171) 171
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3731) 3731
German (53) 53
Russian (42) 42
Chinese (41) 41
Spanish (15) 15
French (14) 14
Japanese (13) 13
Hungarian (9) 9
Italian (6) 6
Polish (5) 5
Portuguese (3) 3
Ukrainian (3) 3
Czech (2) 2
Danish (2) 2
Lithuanian (2) 2
Swedish (2) 2
Dutch (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 12/2007, Volume 82, Issue 6, pp. 726 - 733
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1... 
COA REDUCTASE INHIBITOR | ANION TRANSPORTING POLYPEPTIDE | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | HEALTHY-VOLUNTEERS | INDUCED MYOPATHY | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | CLINICAL-RELEVANCE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Area Under Curve | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Administration, Oral | Pyrimidines - administration & dosage | Liver - metabolism | Rosuvastatin Calcium | Genotype | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Heptanoic Acids - blood | Sulfonamides - administration & dosage
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 07/2005, Volume 78, Issue 1, pp. 60 - 68
Background Myopathy, probably caused by 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibition in skeletal muscle, rarely occurs in patients taking... 
DENSITY-LIPOPROTEIN CHOLESTEROL | SIMVASTATIN 80 MG/DAY | HMG-COA REDUCTASE | PLANT STEROLS | PHARMACOLOGY & PHARMACY | SERUM | UBIQUINONE | LONG-TERM EXPERIENCE | CELL-GROWTH | INHIBITORS | LIPID-ALTERING EFFICACY | Simvastatin - therapeutic use | Electron Transport - drug effects | Age Factors | Cholesterol - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Citrate (si)-Synthase - drug effects | Male | Simvastatin - pharmacology | Hypercholesterolemia - drug therapy | Muscles - pathology | Simvastatin - blood | Patient Selection | Dose-Response Relationship, Drug | Time Factors | Ubiquinone - blood | Adult | Cholesterol, LDL - blood | Female | Citrate (si)-Synthase - metabolism | Muscles - metabolism | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Cholesterol - analogs & derivatives | Sitosterols - blood | Double-Blind Method | Cholesterol, HDL - drug effects | Cholesterol, LDL - drug effects | Pyrroles - blood | Succinate Cytochrome c Oxidoreductase - drug effects | Phytosterols - biosynthesis | Atorvastatin Calcium | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Succinate Cytochrome c Oxidoreductase - metabolism | Phytosterols - blood | Biopsy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Muscles - drug effects | Sex Factors | Cholesterol, HDL - blood | Aged | Cholesterol - biosynthesis | Heptanoic Acids - blood | Ubiquinone - chemistry | Physiological aspects | Medical colleges | Statins | Atherosclerosis
Journal Article
Circulation: Cardiovascular Genetics, ISSN 1942-325X, 08/2013, Volume 6, Issue 4, pp. 400 - 408
BACKGROUND—A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between... 
ATP-binding cassette transporters | Organic anion transporters | Pharmacogenetics | Sodium-independent | Hydroxymethylglutaryl-CoA reductase inhibitors | Pharmacokinetics | POLYMORPHISM MARKEDLY AFFECTS | ABCG2 POLYMORPHISM | CARDIAC & CARDIOVASCULAR SYSTEMS | TRANSPORTERS | SLCO1B1 POLYMORPHISM | HUMANS | BODY CHOLESTEROL-SYNTHESIS | organic anion transporters, sodium-independent | INDUCED MYOPATHY | GENETICS & HEREDITY | pharmacokinetics | hydroxymethylglutaryl-CoA reductase inhibitors | SERUM LATHOSTEROL | SIMVASTATIN | pharmacogenetics | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Pyrimidines - blood | Cholesterol - blood | Heptanoic Acids - pharmacokinetics | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Sulfonamides - blood | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Cytochrome P-450 CYP3A - genetics | Aged, 80 and over | Adult | Female | Retrospective Studies | Fluorobenzenes - blood | Neoplasm Proteins - genetics | Pyrroles - therapeutic use | Databases, Factual | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Alleles | Pyrimidines - pharmacokinetics | Aged | Hydroxycholesterols - blood | Polymorphism, Single Nucleotide | Solute Carrier Organic Anion Transporter Family Member 1b1 | Fluorobenzenes - therapeutic use | Heptanoic Acids - blood | Cohort Studies
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2014, Volume 114, Issue 5, pp. 711 - 715
Journal Article
Journal Article
Epilepsia, ISSN 0013-9580, 11/2011, Volume 52, Issue 11, pp. 2094 - 2104
Summary Purpose:  Statins are selective inhibitors of 3‐hydroxyl‐3‐methyl‐glutaryl coenzyme A (HMG‐CoA) reductase, the rate‐limiting enzyme of the mevalonate... 
Statin | Rat | EEG | Epilepsy | Cholesterol | Blood–brain barrier | Blood-brain barrier | OXIDATIVE STRESS | HMG-COA REDUCTASE | BLOOD-BRAIN-BARRIER | STATINS | CLINICAL NEUROLOGY | QUINOLINIC ACID | HIPPOCAMPAL CELL-DEATH | INDUCED EXCITOTOXICITY | CORTICAL-NEURONS | MICE | INHIBITORS | Rats, Wistar | Cholesterol - blood | Seizures - drug therapy | Anticonvulsants - administration & dosage | Male | Electroencephalography | Simvastatin - pharmacology | Anticonvulsants - pharmacology | Seizures - chemically induced | Anticonvulsants - analysis | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Heptanoic Acids - analysis | Heptanoic Acids - pharmacology | Pentylenetetrazole - pharmacology | Cerebral Cortex - chemistry | Anticonvulsants - blood | Simvastatin - administration & dosage | Pyrroles - analysis | Rats | Pyrroles - blood | Blood-Brain Barrier - metabolism | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Convulsants - pharmacology | Heptanoic Acids - blood | Enzymes | Brain | Thiols | Simvastatin | Amino acids | Liquid chromatography | Permeability | Antilipemic agents | Analysis | Fluorescein | Physiological aspects | Seizures (Medicine) | Mass spectrometry | Injuries | Plasma | Drug therapy | Statins | fluorescein | Stroke | Cortex | Membrane permeability | Mass spectroscopy | Ischemia | Excitotoxicity | statins | Atorvastatin | Coenzyme A | Hydroxymethylglutaryl-CoA reductase | mevalonic acid | Seizures
Journal Article